• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements

    3/18/25 4:17:00 PM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that it filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which also contains certain restated financial statements for periods in fiscal year 2022, 2021 and 2020 (the "2022 Form 10-K"), with the Securities and Exchange Commission ("SEC").

    "This filing represents an important step toward regaining compliance with our financial reporting obligations," said Tom Langan, Interim Chief Executive Officer of Veradigm. "We remain focused on remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing against our growth strategy to deliver end-to-end solutions for our clients, and relisting our common stock. I would like to recognize our Veradigm employees for the dedication and work to earn our customers' business every day."

    "We are pleased to have filed the 2022 Form 10-K as part of a comprehensive undertaking that involved a detailed and thorough examination of our financial statements, as well as our accounting policies and processes," said Lee Westerfield, Interim Chief Financial Officer of Veradigm.

    The adjustments to the Company's revenue from continuing operations in the 2022 Form 10-K are consistent with the amounts that were estimated in the Form 12b-25 filed by the Company on March 4, 2025.

    For further information regarding the circumstances that led to the financial statement restatements and the Company's remediation efforts, please see the sections entitled "Explanatory Note" and Item 9A, "Controls and Procedures", in the 2022 Form 10-K.

    About Veradigm®

    Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

    © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

    Table 1

    Veradigm Inc.

    Condensed Consolidated Balance Sheets

    (In millions)

    (Unaudited)

     

     

     

     

    (As Restated)

     

    (As Restated)

     

     

    December 31,

     

    December 31,

     

    December 31,

     

    2022

     

    2021

     

    2020

    ASSETS
    Current assets:
    Cash and cash equivalents

    $446.6

    $133.7

    $472.8

    Restricted cash

    1.3

    1.3

    5.5

    Accounts receivable, net

    119.1

    119.7

    122.5

    Contract assets

    56.6

    65.2

    63.2

    Income tax receivable

    0.0

    0.0

    25.4

    Prepaid expenses and other current assets

    56.0

    51.8

    47.7

    Current assets attributable to discontinued operations

    0.0

    277.6

    349.2

    Total current assets

    $679.6

    $649.3

    $1,086.3

    Fixed assets, net

    9.5

    17.7

    29.2

    Software development costs, net

    75.1

    81.2

    81.6

    Intangible assets, net

    89.3

    149.7

    166.0

    Goodwill

    532.6

    498.4

    498.6

    Deferred taxes, net

    37.2

    0.0

    0.0

    Contract assets - long-term

    0.0

    0.0

    0.0

    Right-of-use assets - operating leases

    12.0

    18.3

    27.1

    Other assets

    69.4

    79.7

    65.2

    Long-term assets attributable to discontinued operations

    0.0

    816.8

    909.5

    Total assets

    $1,504.7

    $2,311.1

    $2,863.5

     
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable

    $30.9

    $2.2

    $12.8

    Accrued expenses

    66.8

    62.9

    68.3

    Accrued compensation and benefits

    35.9

    30.3

    41.8

    Deferred revenue

    90.1

    87.9

    115.3

    Current operating lease liabilities

    6.6

    6.1

    6.6

    Current liabilities attributable to discontinued operations

    0.0

    299.0

    697.3

    Total current liabilities

    230.3

    488.4

    942.1

    Long-term debt

    200.4

    350.1

    167.6

    Deferred revenue

    0.0

    0.2

    0.1

    Deferred taxes, net

    0.0

    18.7

    18.2

    Long-term operating lease liabilities

    12.4

    16.8

    22.9

    Other liabilities

    44.1

    33.8

    32.5

    Long-term liabilities attributable to discontinued operations

    0.0

    42.7

    66.7

    Total liabilities

    $487.2

    $950.7

    $1,250.1

    Total stockholders' equity

    $1,017.5

    $1,360.4

    $1,613.4

    Total liabilities and stockholders' equity

    $1,504.7

    $2,311.1

    $2,863.5

     
    Table 2
    Veradigm Inc.
    Condensed Consolidated Statements of Operations
    (In millions, except per share amounts)
    (Unaudited)

     

     

     

     

     

    Twelve Months Ended December 31,

     

     

    (As Restated)

     

    (As Restated)

    2022

     

     

    2021

     

     

    2020

     

    Revenue:
    Provider

    $465.9

     

    $478.4

     

    $463.0

     

    Payer & Life Science

    122.1

     

    99.0

     

    93.1

     

    Total Revenue

    588.0

     

    577.4

     

    556.1

     

    Cost of revenue:
    Provider

    232.8

     

    244.2

     

    247.8

     

    Payer & Life Science

    46.8

     

    50.8

     

    44.1

     

    Total cost of revenue

    279.6

     

    295.0

     

    291.9

     

    Gross profit

    308.4

     

    282.4

     

    264.2

     

    Selling, general and administrative expenses

    169.2

     

    111.8

     

    155.7

     

    Research and development

    97.9

     

    84.1

     

    78.6

     

    Asset impairment charges

    7.5

     

    0.5

     

    10.2

     

    Amortization of intangible and acquisition-related assets

    60.9

     

    9.3

     

    11.9

     

    Income (loss) from operations

    (27.1

    )

    76.7

     

    7.8

     

    Interest income (expense), net (a)

    (1.7

    )

    (12.7

    )

    (33.8

    )

    Other income (expense)

    (35.0

    )

    93.7

     

    13.3

     

    Income (loss) before income taxes

    (63.8

    )

    157.7

     

    (12.7

    )

    Income tax (provision) benefit

    43.8

     

    (29.9

    )

    (15.0

    )

    Income (loss) from continuing operations, net of tax

    (20.0

    )

    127.8

     

    (27.7

    )

    Income (loss) from discontinued operations

    (7.1

    )

    15.8

     

    (70.9

    )

    Gain (loss) on sale of discontinued operations

    (10.3

    )

    0.6

     

    1,156.8

     

    Income tax (provision) benefit from discontinued operations

    (49.0

    )

    (4.5

    )

    (362.2

    )

    Income (loss) from discontinued operations, net of tax

    (66.4

    )

    11.9

     

    723.7

     

    Net Income (loss)

    ($86.4

    )

    $139.7

     

    $696.0

     

     
    Diluted earnings per Common Share:
    Income (loss) from continuing operations, net of tax

    ($20.0

    )

    $127.8

     

    ($27.7

    )

    Plus: Interest expense, net of tax1

    $0.0

     

    $0.0

     

    $0.0

     

    Income (loss) from continuing operations2

    (20.0

    )

    127.8

     

    (27.7

    )

    Income (loss) from discontinued operations, net of tax

    (66.4

    )

    11.9

     

    723.7

     

    Net Income (loss)2

    ($86.4

    )

    $139.7

     

    $696.0

     

     
    Income (loss) from continuing operations per share - basic

    ($0.18

    )

    $0.98

     

    ($0.17

    )

    Income (loss) from discontinued operations per share - basic

    ($0.59

    )

    $0.09

     

    $4.54

     

    Income (loss) per share - basic

    ($0.77

    )

    $1.07

     

    $4.37

     

    Income (loss) from continuing operations per share - diluted2

    ($0.18

    )

    $0.92

     

    ($0.17

    )

    Income (loss) from discontinued operations per share - diluted

    ($0.59

    )

    $0.09

     

    $4.54

     

    Income (loss) per share - diluted2

    ($0.77

    )

    $1.01

     

    $4.37

     

     
    Weighted average common shares outstanding:
    Basic

    112.1

     

    130.1

     

    159.3

     

    Diluted

    112.1

     

    138.7

     

    159.3

     

     

    Twelve Months Ended December 31,

     

     

    Restated

     

    Restated

    2022

     

     

    2021

     

     

    2020

     

    (a) Interest income (expense), net
    Interest expense

    (4.1

    )

    (5.4

    )

    (18.3

    )

    Interest income

    4.7

     

    0.2

     

    0.5

     

    Non-cash charges to interest expense

    (2.3

    )

    (7.5

    )

    (16.0

    )

    Interest income (expense), net

    ($1.7

    )

    ($12.7

    )

    ($33.8

    )

    1Associated with 0.875% Convertible Senior Notes
    2Net of tax after the effect of assumed conversions of convertible notes
    Table 3
    Veradigm Inc.
    Condensed Non-GAAP Financial Information
    (In millions, except per share amounts and percentages)
    (Unaudited)
     
    Twelve Months Ended December 31,
    (As

    Restated)
    (As

    Restated)

    2022

    2021

    2020

    Revenue, GAAP

    $588.0

     

    $577.4

     

    $556.1

     

     
    Gross profit, GAAP

    $308.4

     

    $282.4

     

    $264.2

     

    Depreciation and amortization

    37.0

     

    37.5

     

    33.6

     

    Acquisition-related amortization

    6.8

     

    7.1

     

    9.9

     

    Stock-based compensation expense

    1.3

     

    1.1

     

    1.7

     

    Total non-GAAP gross profit

    $353.5

     

    $328.1

     

    $309.4

     

     
    Non-GAAP Gross margin 1

    60.1

    %

    56.8

    %

    55.6

    %

     
     
    Net Income

    ($86.4

    )

    $139.7

     

    $696.0

     

    Less:
    Loss (income) from discontinued operations

    $7.1

     

    ($15.8

    )

    $70.9

     

    Loss (gain) on sale of business, net from discontinued operations

    $10.3

     

    ($0.6

    )

    ($1,156.8

    )

    Income tax provision (benefit) from discontinued operations

    $49.0

     

    $4.5

     

    $362.2

     

    Income (loss) from continuing operations, net of tax, GAAP

    ($20.0

    )

    $127.8

     

    ($27.7

    )

    Plus:
    Interest (income) expense, net

    1.7

     

    12.7

     

    33.8

     

    Other (income) expense

    35.0

     

    (93.7

    )

    (13.3

    )

    Depreciation and amortization

    113.5

     

    65.3

     

    71.2

     

    Income tax (benefit) provision

    (43.8

    )

    29.9

     

    15.0

     

    Stock-based compensation expense

    29.6

     

    13.6

     

    13.5

     

    Asset impairment charges

    7.5

     

    0.5

     

    10.2

     

    Transaction and other

    17.9

     

    12.6

     

    19.6

     

    Adjusted EBITDA

    $141.4

     

    $168.7

     

    $122.3

     

     
    Adjusted EBITDA margin 2

    24.0

    %

    29.2

    %

    22.0

    %

     
    Net Income

    ($86.4

    )

    $139.7

     

    $696.0

     

    Plus: Interest expense, net of tax4

    0.0

     

    0.0

     

    0.0

     

    Net Income (loss)3

    ($86.4

    )

    $139.7

     

    $696.0

     

    Loss (income) from discontinued operations

    7.1

     

    (15.8

    )

    70.9

     

    (Gain) on sale of business, net from discontinued operations

    10.3

     

    (0.6

    )

    (1,156.8

    )

    Income tax provision (benefit) from discontinued operations

    49.0

     

    4.5

     

    362.2

     

    Income (loss) from continuing operations3

    ($20.0

    )

    $127.8

     

    ($27.7

    )

    Less: Interest expense, net of tax4

    0.0

     

    0.0

     

    0.0

     

    Income (loss) from continuing operations, net of tax

    ($20.0

    )

    $127.8

     

    ($27.7

    )

    Acquisition-related amortization

    67.7

     

    16.3

     

    21.7

     

    Stock-based compensation expense

    29.6

     

    13.6

     

    13.5

     

    Transaction and other

    17.9

     

    12.6

     

    19.6

     

    Other non-operating (income) expense

    16.0

     

    0.3

     

    16.5

     

    Asset impairment charges

    7.5

     

    0.0

     

    10.2

     

    Tax rate alignment

    (61.8

    )

    (18.2

    )

    (1.6

    )

    Non-GAAP net income

    $56.9

     

    $152.4

     

    $52.2

     

     
    GAAP effective tax rate

    69

    %

    19

    %

    -120

    %

    Non-GAAP effective tax rate

    24

    %

    24

    %

    24

    %

     
    Weighted shares outstanding - basic

    112.1

     

    130.1

     

    159.3

     

    Weighted shares outstanding - diluted

    112.1

     

    138.7

     

    159.3

     

    The net effect of convertible notes and note hedges

    5.0

     

    (2.8

    )

    2.7

     

    Non-GAAP Weighted shares outstanding - diluted

    117.1

     

    135.9

     

    162.0

     

     
    Income (loss) from continuing operations per share - diluted3

    ($0.18

    )

    $0.92

     

    ($0.17

    )

    Income (loss) from discontinued operations per share - diluted

    ($0.59

    )

    $0.09

     

    $4.54

     

    Income (loss) per share - diluted3

    ($0.77

    )

    $1.01

     

    $4.37

     

    Non-GAAP Income (loss) per share - diluted

    $0.49

     

    $1.12

     

    $0.32

     

     
    1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue.
    2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue.
    3 Net of tax after the effect of assumed conversions of convertible notes
    4 Associated with 0.875% Convertible Senior Notes
    Table 4
    Veradigm Inc.
    Supplemental Condensed Non-GAAP Financial Information
    (In millions, except per share amounts)
    (unaudited)
     

    2020

     

    2021

     

     

     

     

     

    2022

     

     

     

     

     

    (As Restated)

    (As Restated)

    (As Restated)

    (As Restated)

    (As Restated)

    Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total
    Provider
    Revenue

    $463.0

     

    $113.2

     

    $117.3

     

    $118.7

     

    $129.2

     

    $478.4

     

    $113.4

     

    $114.1

     

    $116.0

     

    $122.4

     

    $465.9

     

    Gross profit, Non-GAAP

    $254.6

     

    $63.3

     

    $65.7

     

    $64.4

     

    $77.5

     

    $270.9

     

    $64.6

     

    $63.0

     

    $66.6

     

    $73.2

     

    $267.4

     

    Gross margin, Non-GAAP 1

    55.0

    %

    55.9

    %

    56.0

    %

    54.3

    %

    60.0

    %

    56.6

    %

    57.0

    %

    55.2

    %

    57.4

    %

    59.8

    %

    57.4

    %

     
    Payer & Life Science
    Revenue

    $93.1

     

    $21.6

     

    $23.7

     

    $25.7

     

    $28.0

     

    $99.0

     

    $23.5

     

    $34.4

     

    $30.4

     

    $33.8

     

    $122.1

     

    Gross profit, Non-GAAP

    $54.8

     

    $11.9

     

    $13.6

     

    $14.8

     

    $16.9

     

    $57.2

     

    $14.8

     

    $24.7

     

    $21.5

     

    $25.1

     

    $86.1

     

    Gross margin, Non-GAAP 1

    58.9

    %

    55.1

    %

    57.4

    %

    57.6

    %

    60.4

    %

    57.8

    %

    63.0

    %

    71.8

    %

    70.7

    %

    74.3

    %

    70.5

    %

    Total Veradigm
    Revenue

    $556.1

     

    $134.8

     

    $141.0

     

    $144.4

     

    $157.2

     

    $577.4

     

    $136.9

     

    $148.5

     

    $146.4

     

    $156.2

     

    $588.0

     

    Gross profit, Non-GAAP

    $309.4

     

    $75.2

     

    $79.3

     

    $79.2

     

    $94.4

     

    $328.1

     

    $79.4

     

    $87.7

     

    $88.1

     

    $98.3

     

    $353.5

     

    Gross margin, Non-GAAP 1

    55.6

    %

    55.8

    %

    56.2

    %

    54.8

    %

    60.1

    %

    56.8

    %

    58.0

    %

    59.1

    %

    60.2

    %

    62.9

    %

    60.1

    %

    Adjusted EBITDA

    $122.3

     

    $32.4

     

    $38.9

     

    $36.8

     

    $60.6

     

    $168.7

     

    $27.7

     

    $37.5

     

    $33.9

     

    $42.3

     

    $141.4

     

    Adjusted EBITDA margin2

    22.0

    %

    24.0

    %

    27.6

    %

    25.5

    %

    38.5

    %

    29.2

    %

    20.2

    %

    25.3

    %

    23.2

    %

    27.1

    %

    24.0

    %

    Net Income, Non-GAAP

    $52.2

     

    $14.8

     

    $28.8

     

    $27.2

     

    $81.6

     

    $152.4

     

    $10.5

     

    $6.6

     

    $15.7

     

    $24.0

     

    $56.9

     

    Non-GAAP Weighted shares outstanding - diluted

    162.0

     

    146.5

     

    142.0

     

    128.6

     

    125.3

     

    135.9

     

    125.1

     

    119.6

     

    113.3

     

    111.1

     

    117.1

     

    Non-GAAP Income (loss) per share - diluted

    $0.32

     

    $0.10

     

    $0.20

     

    $0.21

     

    $0.65

     

    $1.12

     

    $0.08

     

    $0.06

     

    $0.14

     

    $0.22

     

    $0.49

     

     
    1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue.
    2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue.
     
    Table 5
    Veradigm Inc.
    Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details
    (In millions)
    (unaudited)
     

    2020

     

     

    2021

     

     

     

     

     

     

    2022

     

     

     

     

     

    (As Restated)

     

    (As Restated)

     

    (As Restated)

    (As Restated)

    (As Restated)

     

    Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total
    Provider
    Revenue

    $463.0

     

    $113.2

     

    $117.3

     

    $118.7

     

    $129.2

     

    $478.4

     

    $113.4

     

    $114.1

     

    $116.0

     

    $122.4

     

    $465.9

     

     
    Gross profit, GAAP

    $215.2

     

    $54.2

     

    $56.4

     

    $55.2

     

    $68.4

     

    $234.2

     

    $55.9

     

    $54.7

     

    $58.3

     

    $64.2

     

    $233.1

     

    Depreciation and amortization

    29.8

     

    7.7

     

    7.9

     

    7.8

     

    7.1

     

    30.5

     

    7.2

     

    6.9

     

    6.8

     

    7.5

     

    28.4

     

    Acquisition-related amortization

    8.1

     

    1.3

     

    1.3

     

    1.3

     

    1.4

     

    5.3

     

    1.1

     

    1.1

     

    1.1

     

    1.4

     

    4.7

     

    Stock-based compensation expense

    1.5

     

    0.1

     

    0.1

     

    0.1

     

    0.6

     

    0.9

     

    0.4

     

    0.3

     

    0.4

     

    0.1

     

    1.2

     

    Gross profit, Non-GAAP

    $254.6

     

    $63.3

     

    $65.7

     

    $64.4

     

    $77.5

     

    $270.9

     

    $64.6

     

    $63.0

     

    $66.6

     

    $73.2

     

    $267.4

     

    Payer & Life Science
    Revenue

    $93.1

     

    $21.6

     

    $23.7

     

    $25.7

     

    $28.0

     

    $99.0

     

    $23.5

     

    $34.4

     

    $30.4

     

    $33.8

     

    $122.1

     

     
    Gross profit, GAAP

    $49.0

     

    $9.6

     

    $11.3

     

    $12.4

     

    $14.9

     

    $48.2

     

    $12.1

     

    $21.9

     

    $18.7

     

    $22.6

     

    $75.3

     

    Depreciation and amortization

    3.8

     

    1.7

     

    1.7

     

    1.8

     

    1.8

     

    7.0

     

    2.2

     

    2.2

     

    2.2

     

    2.0

     

    8.6

     

    Acquisition-related amortization

    1.8

     

    0.5

     

    0.5

     

    0.5

     

    0.3

     

    1.8

     

    0.5

     

    0.6

     

    0.6

     

    0.4

     

    2.1

     

    Stock-based compensation expense

    0.2

     

    0.1

     

    0.1

     

    0.1

     

    (0.1

    )

    0.2

     

    0.0

     

    0.0

     

    0.0

     

    0.1

     

    0.1

     

    Gross profit, Non-GAAP

    $54.8

     

    $11.9

     

    $13.6

     

    $14.8

     

    $16.9

     

    $57.2

     

    $14.8

     

    $24.7

     

    $21.5

     

    $25.1

     

    $86.1

     

     
    Table 6
    Veradigm Inc.
    Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details
    (In millions, except per share amounts)
    (unaudited)
     

    2020

     

     

    2021

     

     

     

     

     

     

    2022

     

     

     

     

     

    (As Restated)

     

    (As Restated)

     

    (As Restated)

    (As Restated)

    (As Restated)

     

     

    Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total
    Total Veradigm
    Revenue

    $556.1

     

    $134.8

     

    $141.0

     

    $144.4

     

    $157.2

     

    $577.4

     

    $136.9

     

    $148.5

     

    $146.4

     

    $156.2

     

    $588.0

     

     
    Gross profit, GAAP

    $264.2

     

    $63.8

     

    $67.7

     

    $67.6

     

    $83.3

     

    $282.4

     

    $68.0

     

    $76.6

     

    $77.0

     

    $86.8

     

    $308.4

     

    Depreciation and amortization

    33.6

     

    9.4

     

    9.6

     

    9.6

     

    8.9

     

    37.5

     

    9.4

     

    9.1

     

    9.0

     

    9.5

     

    37.0

     

    Acquisition-related amortization

    9.9

     

    1.8

     

    1.8

     

    1.8

     

    1.7

     

    7.1

     

    1.6

     

    1.7

     

    1.7

     

    1.8

     

    6.8

     

    Stock-based compensation expense

    1.7

     

    0.2

     

    0.2

     

    0.2

     

    0.5

     

    1.1

     

    0.4

     

    0.3

     

    0.4

     

    0.2

     

    1.3

     

    Gross profit, Non-GAAP

    $309.4

     

    $75.2

     

    $79.3

     

    $79.2

     

    $94.4

     

    $328.1

     

    $79.4

     

    $87.7

     

    $88.1

     

    $98.3

     

    $353.5

     

     
    Net Income (loss)

    $696.0

     

    $20.3

     

    $31.4

     

    $14.3

     

    $73.7

     

    $139.7

     

    $23.6

     

    ($83.0

    )

    ($0.4

    )

    ($26.6

    )

    ($86.4

    )

    Interest expense, net of tax2

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.5

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    Net Income (loss)1

    $696.0

     

    $20.3

     

    $31.4

     

    $14.3

     

    $73.7

     

    $139.7

     

    $24.1

     

    ($83.0

    )

    ($0.4

    )

    ($26.6

    )

    ($86.4

    )

    Loss (income) from discontinued operations

    70.9

     

    (19.0

    )

    (3.2

    )

    6.8

     

    (0.4

    )

    (15.8

    )

    4.3

     

    3.0

     

    0.5

     

    (0.7

    )

    7.1

     

    Loss (gain) on sale of business, net from discontinued operations

    (1,156.8

    )

    (0.6

    )

    0.0

     

    0.0

     

    0.0

     

    (0.6

    )

    0.0

     

    10.3

     

    0.0

     

    0.0

     

    10.3

     

    Income tax provision (benefit) from discontinued operations

    362.2

     

    5.1

     

    0.2

     

    (2.0

    )

    1.2

     

    4.5

     

    (9.8

    )

    61.4

     

    (3.0

    )

    0.4

     

    49.0

     

    Income (loss) from continuing operations1

    ($27.7

    )

    $5.8

     

    $28.4

     

    $19.1

     

    $74.5

     

    $127.8

     

    $18.6

     

    ($8.3

    )

    ($2.9

    )

    ($26.9

    )

    ($20.0

    )

    Interest expense, net of tax2

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    (0.5

    )

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    Net Income (loss) from continuing operations, GAAP

    ($27.7

    )

    $5.8

     

    $28.4

     

    $19.1

     

    $74.5

     

    $127.8

     

    $18.1

     

    ($8.3

    )

    ($2.9

    )

    ($26.9

    )

    ($20.0

    )

    Interest (income) expense, net

    33.8

     

    2.8

     

    2.9

     

    3.6

     

    3.4

     

    12.7

     

    2.1

     

    1.8

     

    (0.4

    )

    (1.8

    )

    1.7

     

    Other (income) expense

    (13.3

    )

    (1.2

    )

    (18.3

    )

    (14.0

    )

    (60.2

    )

    (93.7

    )

    (0.1

    )

    30.0

     

    3.9

     

    1.2

     

    35.0

     

    Depreciation and amortization

    71.2

     

    16.7

     

    16.7

     

    16.5

     

    15.4

     

    65.3

     

    15.7

     

    28.4

     

    34.6

     

    34.8

     

    113.5

     

    Income tax (benefit) provision

    15.0

     

    2.9

     

    3.6

     

    5.9

     

    17.5

     

    29.9

     

    (23.7

    )

    (28.0

    )

    (10.0

    )

    17.9

     

    (43.8

    )

    Stock-based compensation expense

    13.5

     

    3.6

     

    3.5

     

    3.2

     

    3.3

     

    13.6

     

    6.9

     

    10.5

     

    5.7

     

    6.5

     

    29.6

     

    Asset impairment charges

    10.2

     

    0.0

     

    0.2

     

    0.4

     

    (0.1

    )

    0.5

     

    2.0

     

    0.4

     

    1.2

     

    3.9

     

    7.5

     

    Transaction and other

    19.6

     

    1.8

     

    1.9

     

    2.1

     

    6.8

     

    12.6

     

    6.7

     

    2.7

     

    1.8

     

    6.7

     

    17.9

     

    Adjusted EBITDA

    $122.3

     

    $32.4

     

    $38.9

     

    $36.8

     

    $60.6

     

    $168.7

     

    $27.7

     

    $37.5

     

    $33.9

     

    $42.3

     

    $141.4

     

     
    Income (loss) from continuing operations, net of tax, as reported

    ($27.7

    )

    $5.8

     

    $28.4

     

    $19.1

     

    $74.5

     

    $127.8

     

    $18.1

     

    ($8.3

    )

    ($2.9

    )

    ($26.9

    )

    ($20.0

    )

    Acquisition-related amortization

    21.7

     

    4.1

     

    4.1

     

    4.1

     

    4.0

     

    16.3

     

    3.8

     

    17.0

     

    23.5

     

    23.4

     

    67.7

     

    Stock-based compensation expense

    13.5

     

    3.6

     

    3.5

     

    3.2

     

    3.3

     

    13.6

     

    6.9

     

    10.5

     

    5.7

     

    6.5

     

    29.6

     

    Transaction and other

    19.6

     

    1.8

     

    1.9

     

    2.1

     

    6.8

     

    12.6

     

    6.7

     

    2.7

     

    1.8

     

    6.7

     

    17.9

     

    Other non-operating (income) expense

    16.5

     

    1.3

     

    (3.6

    )

    1.3

     

    1.3

     

    0.3

     

    0.0

     

    14.4

     

    1.4

     

    0.2

     

    16.0

     

    (Gain) loss on business transactions

    0.0

     

    0.0

     

    0.0

     

    (0.0

    )

    0.0

     

    (0.0

    )

    0.0

     

    0.0

     

    0.0

     

    (0.0

    )

    (0.0

    )

    Asset impairment charges

    10.2

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    0.0

     

    2.0

     

    0.4

     

    1.2

     

    3.9

     

    7.5

     

    Tax rate alignment

    (1.6

    )

    (1.8

    )

    (5.5

    )

    (2.6

    )

    (8.3

    )

    (18.2

    )

    (27.0

    )

    (30.1

    )

    (15.0

    )

    10.2

     

    (61.8

    )

    Non-GAAP net income

    $52.2

     

    $14.8

     

    $28.8

     

    $27.2

     

    $81.6

     

    $152.4

     

    $10.5

     

    $6.6

     

    $15.7

     

    $24.0

     

    $56.9

     

     
    GAAP effective tax rate

    -120

    %

    34

    %

    11

    %

    24

    %

    19

    %

    19

    %

    425

    %

    77

    %

    77

    %

    -201

    %

    69

    %

    Non-GAAP effective tax rate

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

    24

    %

     
    Weighted shares outstanding - basic

    159.3

     

    140.2

     

    136.6

     

    123.9

     

    120.1

     

    130.1

     

    115.9

     

    114.3

     

    110.2

     

    108.1

     

    112.1

     

    Weighted shares outstanding - diluted

    162.0

     

    149.1

     

    145.3

     

    131.4

     

    127.8

     

    138.7

     

    138.7

     

    118.7

     

    113.3

     

    111.1

     

    116.8

     

    Less the net effect of convertible notes and note hedges

    0.0

     

    (2.6

    )

    (3.3

    )

    (2.8

    )

    (2.5

    )

    (2.8

    )

    (13.6

    )

    0.9

     

    0.0

     

    0.0

     

    0.3

     

    Non-GAAP Weighted shares outstanding - diluted

    162.0

     

    146.5

     

    142.0

     

    128.6

     

    125.3

     

    135.9

     

    125.1

     

    119.6

     

    113.3

     

    111.1

     

    117.1

     

     
    Income (loss) from continuing operations per share - diluted2

    ($0.17

    )

    $0.04

     

    $0.20

     

    $0.15

     

    $0.58

     

    $0.92

     

    $0.13

     

    ($0.07

    )

    ($0.03

    )

    ($0.25

    )

    ($0.18

    )

    Income (loss) from discontinued operations per share - diluted

    $4.54

     

    $0.10

     

    $0.02

     

    ($0.04

    )

    ($0.01

    )

    $0.09

     

    $0.04

     

    ($0.65

    )

    $0.02

     

    $0.00

     

    ($0.59

    )

    Income (loss) per share - diluted2

    $4.37

     

    $0.14

     

    $0.22

     

    $0.11

     

    $0.57

     

    $1.01

     

    $0.17

     

    ($0.72

    )

    ($0.01

    )

    ($0.25

    )

    ($0.77

    )

    Non-GAAP Net Income (loss) per share - diluted

    $0.32

     

    $0.10

     

    $0.20

     

    $0.21

     

    $0.65

     

    $1.12

     

    $0.08

     

    $0.06

     

    $0.14

     

    $0.22

     

    $0.49

     

    1Net of tax after the effect of assumed conversions of convertible notes
    2Associated with 0.875% Convertible Senior Notes

    Explanation of Non-GAAP Financial Measures

    Veradigm reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Veradigm presents non-GAAP gross profit, gross margin, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income (loss), diluted weighted shares outstanding and diluted income (loss) per share, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures are presented below:

    • Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related amortization; stock-based compensation expense; and depreciation and amortization. Reconciliations to GAAP gross profit are found in Tables 3, 5, and 6 within this press release.
    • Non-GAAP gross margin is a non-GAAP measure that is calculated by dividing non-GAAP gross profit by revenue.
    • Adjusted EBITDA is a non-GAAP financial measure and consists of GAAP net income/(loss) from continuing operations and adjusts for: interest (income)/expense, net; other (income)/expense; depreciation and amortization; income tax (benefit)/provision; stock-based compensation expense; asset impairment charges; and transaction and other revenue and expenses. Reconciliations to GAAP net income/(loss) are found in Tables 3 and 6 within this press release.
    • Adjusted EBITDA margin is a non-GAAP measure that is calculated by dividing Adjusted EBITDA by revenue. See the reconciliations in Tables 3 and 6 within this press release with respect to Adjusted EBITDA.
    • Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Veradigm effective state income tax rate and adjustments for permanent differences.
    • Non-GAAP net income (loss) consists of GAAP net income/(loss), as reported, less discontinued operations and adds back acquisition-related amortization; stock-based compensation expense; asset impairment charges; transaction and other revenue and expenses; and non-cash charges to interest expense and other. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income (loss) are found in Tables 3 and 6 within this press release.
    • Non-GAAP diluted weighted shares outstanding consists of diluted weighted shares outstanding, as reported, less the dilutive impact of the Company's 0.875% convertible notes (the "convertible notes") due to the intent to settle the principal in cash and shares to be delivered at settlement by the convertible note hedge.
    • Non-GAAP diluted income (loss) per share consists of non-GAAP net income, as defined above, divided by non-GAAP diluted weighted shares outstanding, as defined above, during the applicable period.

    Management believes that non-GAAP gross profit, gross margin, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income (loss), diluted weighted shares outstanding and diluted income (loss) per share provide useful supplemental information to management and investors regarding the underlying performance of Veradigm business operations. Acquisition accounting adjustments and transaction and other revenue and expenses recorded in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.

    Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP diluted income (loss) per share and Adjusted EBITDA to measure achievement under Veradigm's stock and cash incentive compensation plans. Note, however, that non-GAAP diluted income (loss) per share and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity.

    Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Veradigm's results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within this press release.

    Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Veradigm excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income, Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such expenses in any specific period may not directly correlate with the underlying performance of Veradigm's business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

    Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Veradigm excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income (loss) and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.

    Asset impairment charges. Asset impairment charges, which are excluded from Adjusted EBITDA, Adjusted EBITDA margin and Non-GAAP net income (loss), reflect non-cash charges related to the abandonment of certain leased spaces and write-offs based on management's assessment of the likelihood of near-term recovery of certain investments' value.

    Depreciation and Amortization. Depreciation and amortization, which are excluded from non-GAAP gross profit, non-GAAP gross margin, Adjusted EBITDA and Adjusted EBITDA margin, are non-cash expenses arising from allocating the cost of fixed assets, intangibles and capitalized software over time.

    Transaction and Other. Transaction and other revenue and expenses relate to certain favorable and unfavorable legal settlements, severance, investigations, internal reviews, restatement-related accounting and legal advisory services and other charges incurred in connection with activities that are considered not reflective of our core business. Veradigm excludes transaction and other revenue and expenses from non-GAAP net income (loss), Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such revenue or expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such revenue or expenses can vary significantly between periods.

    Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the discount and debt issuance costs associated with the convertible notes. Other includes certain other income and expense and impairments on long-term investments and gains and losses on business transactions and certain asset disposals.

    Tax Rate Alignment. Tax rate alignment aligns the applicable period's effective tax rate to the expected annual non-GAAP effective tax rate.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250318984157/en/

    Investors:

    Jenny Gelinas

    312-506-1237

    [email protected]

    Media:

    Amanda Cohen

    412-919-2417

    [email protected]

    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/14/24 1:11:13 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/8/24 10:29:29 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Veradigm downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

      3/19/24 7:50:39 AM ET
      $MDRX
      EDP Services
      Technology
    • Barclays initiated coverage on Veradigm with a new price target

      Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

      1/3/24 8:00:02 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Argus

      Argus downgraded Veradigm from Buy to Hold

      7/6/23 9:00:49 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    See more

    $MDRX
    SEC Filings

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sprinklr Set to Join S&P SmallCap 600

      NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

      2/28/24 5:50:00 PM ET
      $CXM
      $MDRX
      $SPGI
      Computer Software: Prepackaged Software
      Technology
      EDP Services
      Finance: Consumer Services
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/22/25 4:23:28 PM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/17/25 5:02:25 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form 8-K/A filed by Veradigm Inc.

      8-K/A - Veradigm Inc. (0001124804) (Filer)

      4/10/25 4:10:53 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

      4/A - Veradigm Inc. (0001124804) (Issuer)

      3/15/24 5:16:45 PM ET
      $MDRX
      EDP Services
      Technology
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      3/4/24 9:50:46 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency

      Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath. Veradigm Revenue Cycle Services provides a robust suite of solu

      4/2/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Langan Thomas covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.57% to 327,528 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      5/5/25 4:08:52 PM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 2,481 shares, decreasing direct ownership by 0.75% to 329,421 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/3/25 4:55:05 PM ET
      $MDRX
      EDP Services
      Technology
    • SVP & Chief HR Officer Hammond Lisa covered exercise/tax liability with 227 shares, decreasing direct ownership by 0.19% to 119,648 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/2/25 4:57:39 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

      3/13/25 9:57:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

      Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

      1/30/25 4:02:00 PM ET
      $MDRX
      EDP Services
      Technology